Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients

Abstract Most patients infected with SARS-CoV-2 are asymptomatic or mildly symptomatic. However, the early and late antibody kinetics, and the association between antibody levels, clinical symptoms, and disease phase in these patients have not yet been fully defined. Confirmed SARS-CoV-2 patients an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shai Efrati, Merav Catalogna, Ramzia Abu Hamed, Amir Hadanny, Adina Bar-Chaim, Patricia Benveniste-Levkovitz, Refael Strugo, Osnat Levtzion-korach
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6d96d027b0354b4aab45a096bfa175fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6d96d027b0354b4aab45a096bfa175fc
record_format	dspace
spelling	oai:doaj.org-article:6d96d027b0354b4aab45a096bfa175fc2021-12-02T14:33:51ZEarly and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients10.1038/s41598-021-93175-y2045-2322https://doaj.org/article/6d96d027b0354b4aab45a096bfa175fc2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93175-yhttps://doaj.org/toc/2045-2322Abstract Most patients infected with SARS-CoV-2 are asymptomatic or mildly symptomatic. However, the early and late antibody kinetics, and the association between antibody levels, clinical symptoms, and disease phase in these patients have not yet been fully defined. Confirmed SARS-CoV-2 patients and their household contacts were evaluated over a period four months. The evaluation procedure included symptom monitoring, viral load and serology analysis every ten days. A total of 1334 serum samples were collected from 135 patients and analyzed using three assays for IgG-N, IgG-S and IgM antibodies. Of the study participants, 97% were seropositive during the study, and two distinct clusters were identified. These clusters were significantly different in their inflammatory related symptoms. Peak IgG-S was 40.0 AU/ml for the non-inflammatory cluster and 71.5 AU/ml for the inflammatory cluster (P = 0.006), whereas IgG-N peaks were 4.3 and 5.87 (P = 0.023) respectively. Finally, a decision tree model was designed to predict the disease phase based on the serological titer levels, and had an overall accuracy of 80.7%. The specific profile of seroconversion and decay of serum antibodies can be used to predict the time-course from the acute infection.Shai EfratiMerav CatalognaRamzia Abu HamedAmir HadannyAdina Bar-ChaimPatricia Benveniste-LevkovitzRefael StrugoOsnat Levtzion-korachNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shai Efrati Merav Catalogna Ramzia Abu Hamed Amir Hadanny Adina Bar-Chaim Patricia Benveniste-Levkovitz Refael Strugo Osnat Levtzion-korach Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients
description	Abstract Most patients infected with SARS-CoV-2 are asymptomatic or mildly symptomatic. However, the early and late antibody kinetics, and the association between antibody levels, clinical symptoms, and disease phase in these patients have not yet been fully defined. Confirmed SARS-CoV-2 patients and their household contacts were evaluated over a period four months. The evaluation procedure included symptom monitoring, viral load and serology analysis every ten days. A total of 1334 serum samples were collected from 135 patients and analyzed using three assays for IgG-N, IgG-S and IgM antibodies. Of the study participants, 97% were seropositive during the study, and two distinct clusters were identified. These clusters were significantly different in their inflammatory related symptoms. Peak IgG-S was 40.0 AU/ml for the non-inflammatory cluster and 71.5 AU/ml for the inflammatory cluster (P = 0.006), whereas IgG-N peaks were 4.3 and 5.87 (P = 0.023) respectively. Finally, a decision tree model was designed to predict the disease phase based on the serological titer levels, and had an overall accuracy of 80.7%. The specific profile of seroconversion and decay of serum antibodies can be used to predict the time-course from the acute infection.
format	article
author	Shai Efrati Merav Catalogna Ramzia Abu Hamed Amir Hadanny Adina Bar-Chaim Patricia Benveniste-Levkovitz Refael Strugo Osnat Levtzion-korach
author_facet	Shai Efrati Merav Catalogna Ramzia Abu Hamed Amir Hadanny Adina Bar-Chaim Patricia Benveniste-Levkovitz Refael Strugo Osnat Levtzion-korach
author_sort	Shai Efrati
title	Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients
title_short	Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients
title_full	Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients
title_fullStr	Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients
title_full_unstemmed	Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients
title_sort	early and long term antibody kinetics of asymptomatic and mild disease covid-19 patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6d96d027b0354b4aab45a096bfa175fc
work_keys_str_mv	AT shaiefrati earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT meravcatalogna earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT ramziaabuhamed earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT amirhadanny earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT adinabarchaim earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT patriciabenvenistelevkovitz earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT refaelstrugo earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients AT osnatlevtzionkorach earlyandlongtermantibodykineticsofasymptomaticandmilddiseasecovid19patients
_version_	1718391134265278464

Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients

Ejemplares similares